CD63 and COVID-19: Interestingly, plasma from COVID-19 patients triggered platelet activation in vitro, as demonstrated by a significant increase in platelet P-selectin and CD63 surface translocation and platelet-leukocyte aggregates formation (94, 112), which was dampened by pretreatment with IL-6 receptor inhibitor (113).